FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3002622012> ?p ?o ?g. }

• W3002622012 endingPage "101957" @default.
• W3002622012 startingPage "101957" @default.
• W3002622012 abstract "Background Patient satisfaction with treatment in relapsing-remitting multiple sclerosis (RRMS) has a direct impact on adherence to treatment and, consequently, upon treatment outcomes and costs. Patient-reported outcomes (PROs) are a common method for determining patient satisfaction in MS and other diseases. Methods The 12-month, open-label, Phase IV CONFIDENCE study assessed patient satisfaction and treatment adherence, using PROs, as well as safety outcomes in patients with RRMS treated with glatiramer acetate (GA). In the previously reported (Cutter et al., 2019) initial 6-month core phase of the study, patients were randomized to receive three-times-weekly (TIW) GA 40 mg/mL (GA40; n = 431) or once-daily GA 20 mg/mL (GA20; n = 430). In the 6-month, single-arm extension phase, 789 patients completing the core phase were treated with GA40 to determine whether benefits observed in the core phase were sustained during the extension phase, to ascertain if switching from GA20 to GA40 resulted in PRO changes, and to assess safety outcomes. Results Superior PRO scores for patient satisfaction with treatment, patient perception of treatment convenience, and symptomatic changes (fatigue impact and mental health) observed in the GA40 group versus the GA20 group in the core phase were all maintained in the extension phase. Treatment adherence, significantly greater in the GA40 versus the GA20 group in the core phase, was sustained in patients continuing to receive GA40 in the extension phase, while those who switched from GA20 to GA40 increased their adherence during the extension phase. Safety variables remained consistent throughout the study, with no notable changes observed in patients switching from GA20 to GA40. Conclusions Data from the extension phase of the CONFIDENCE study show that the benefits associated with GA40 treatment in terms of medication satisfaction, treatment convenience perception, symptomatic changes in fatigue impact and mental health status, and treatment adherence were maintained over a 12-month observation period. These results confirm the preferential utility of GA40 versus GA20 in clinical practice, with no additional safety concerns associated with switching from GA20 to GA40." @default.
• W3002622012 created "2020-01-30" @default.
• W3002622012 creator A5001299036 @default.
• W3002622012 creator A5009693047 @default.
• W3002622012 creator A5010074689 @default.
• W3002622012 creator A5016403553 @default.
• W3002622012 creator A5023360727 @default.
• W3002622012 creator A5026360523 @default.
• W3002622012 creator A5033244767 @default.
• W3002622012 creator A5036008316 @default.
• W3002622012 creator A5074920564 @default.
• W3002622012 creator A5079049956 @default.
• W3002622012 creator A5083744505 @default.
• W3002622012 creator A5088430812 @default.
• W3002622012 date "2020-05-01" @default.
• W3002622012 modified "2023-10-01" @default.
• W3002622012 title "Satisfaction and adherence with glatiramer acetate 40mg/mL TIW in RRMS after 12 months, and the effect of switching from 20mg/mL QD" @default.
• W3002622012 cites W1580917658 @default.
• W3002622012 cites W1989806530 @default.
• W3002622012 cites W2005506388 @default.
• W3002622012 cites W2025177594 @default.
• W3002622012 cites W2048018021 @default.
• W3002622012 cites W2056568077 @default.
• W3002622012 cites W2061166054 @default.
• W3002622012 cites W2097587877 @default.
• W3002622012 cites W2112165124 @default.
• W3002622012 cites W2122545833 @default.
• W3002622012 cites W2127391795 @default.
• W3002622012 cites W2133755641 @default.
• W3002622012 cites W2144317224 @default.
• W3002622012 cites W2154299978 @default.
• W3002622012 cites W2311072866 @default.
• W3002622012 cites W2326826867 @default.
• W3002622012 cites W2474097887 @default.
• W3002622012 cites W2560881614 @default.
• W3002622012 cites W2726265683 @default.
• W3002622012 cites W2804885025 @default.
• W3002622012 cites W2944811127 @default.
• W3002622012 cites W4366064463 @default.
• W3002622012 doi "https://doi.org/10.1016/j.msard.2020.101957" @default.
• W3002622012 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32028117" @default.
• W3002622012 hasPublicationYear "2020" @default.
• W3002622012 type Work @default.
• W3002622012 sameAs 3002622012 @default.
• W3002622012 citedByCount "5" @default.
• W3002622012 countsByYear W30026220122021 @default.
• W3002622012 countsByYear W30026220122022 @default.
• W3002622012 crossrefType "journal-article" @default.
• W3002622012 hasAuthorship W3002622012A5001299036 @default.
• W3002622012 hasAuthorship W3002622012A5009693047 @default.
• W3002622012 hasAuthorship W3002622012A5010074689 @default.
• W3002622012 hasAuthorship W3002622012A5016403553 @default.
• W3002622012 hasAuthorship W3002622012A5023360727 @default.
• W3002622012 hasAuthorship W3002622012A5026360523 @default.
• W3002622012 hasAuthorship W3002622012A5033244767 @default.
• W3002622012 hasAuthorship W3002622012A5036008316 @default.
• W3002622012 hasAuthorship W3002622012A5074920564 @default.
• W3002622012 hasAuthorship W3002622012A5079049956 @default.
• W3002622012 hasAuthorship W3002622012A5083744505 @default.
• W3002622012 hasAuthorship W3002622012A5088430812 @default.
• W3002622012 hasConcept C118552586 @default.
• W3002622012 hasConcept C126322002 @default.
• W3002622012 hasConcept C141071460 @default.
• W3002622012 hasConcept C168563851 @default.
• W3002622012 hasConcept C1862650 @default.
• W3002622012 hasConcept C197934379 @default.
• W3002622012 hasConcept C2775944032 @default.
• W3002622012 hasConcept C2778577042 @default.
• W3002622012 hasConcept C2780640218 @default.
• W3002622012 hasConcept C44249647 @default.
• W3002622012 hasConcept C71924100 @default.
• W3002622012 hasConceptScore W3002622012C118552586 @default.
• W3002622012 hasConceptScore W3002622012C126322002 @default.
• W3002622012 hasConceptScore W3002622012C141071460 @default.
• W3002622012 hasConceptScore W3002622012C168563851 @default.
• W3002622012 hasConceptScore W3002622012C1862650 @default.
• W3002622012 hasConceptScore W3002622012C197934379 @default.
• W3002622012 hasConceptScore W3002622012C2775944032 @default.
• W3002622012 hasConceptScore W3002622012C2778577042 @default.
• W3002622012 hasConceptScore W3002622012C2780640218 @default.
• W3002622012 hasConceptScore W3002622012C44249647 @default.
• W3002622012 hasConceptScore W3002622012C71924100 @default.
• W3002622012 hasFunder F4320307778 @default.
• W3002622012 hasLocation W30026220121 @default.
• W3002622012 hasOpenAccess W3002622012 @default.
• W3002622012 hasPrimaryLocation W30026220121 @default.
• W3002622012 hasRelatedWork W102576517 @default.
• W3002622012 hasRelatedWork W2028896626 @default.
• W3002622012 hasRelatedWork W2108647028 @default.
• W3002622012 hasRelatedWork W2119662385 @default.
• W3002622012 hasRelatedWork W2147912507 @default.
• W3002622012 hasRelatedWork W2259084066 @default.
• W3002622012 hasRelatedWork W2396047537 @default.
• W3002622012 hasRelatedWork W2775342387 @default.
• W3002622012 hasRelatedWork W3150078158 @default.
• W3002622012 hasRelatedWork W6143703 @default.
• W3002622012 hasVolume "40" @default.
• W3002622012 isParatext "false" @default.

• next